Claus Andersson

Claus Andersson is a General Partner at Sunstone Life Science Ventures who recently joined the Board of Directors at Resalis Therapeutics.13 His appointment to the board came in conjunction with Sunstone Life Science Ventures leading a €10 million Series A financing round for Resalis Therapeutics.14

Professional Background

Claus Andersson has extensive experience in the biotech and life sciences sector. As a General Partner at Sunstone Life Science Ventures, he plays a key role in identifying and investing in promising life science companies.5 His expertise likely includes evaluating potential investments, providing strategic guidance, and supporting portfolio companies' growth.

Board Positions

In addition to his new role at Resalis Therapeutics, Claus Andersson serves on the Board of Directors for multiple biotech companies, including:

• DiogenX
• Rewind Therapeutics
• Cardior Pharmaceuticals5

Involvement with Resalis Therapeutics

Claus Andersson's involvement with Resalis Therapeutics is significant for several reasons:

1. Investment Leadership: He led Sunstone Life Science Ventures' participation in Resalis' €10 million Series A funding round.12

2. Strategic Guidance: As a board member, he will likely provide valuable insights and guidance to help Resalis advance its lead program, RES-010, through clinical trials.1

3. Industry Expertise: His experience in the life sciences sector could be instrumental in helping Resalis navigate the challenges of developing innovative therapies for obesity and metabolic disorders.3

Claus Andersson's addition to the Resalis board underscores Sunstone Life Science Ventures' confidence in the company's approach to treating obesity and its potential to make a significant impact in the field of metabolic disorders.1